Literature DB >> 17534891

Malignant ascites protect against TRAIL-induced apoptosis by activating the PI3K/Akt pathway in human ovarian carcinoma cells.

Denis Lane1, Véronique Robert, Roxanne Grondin, Claudine Rancourt, Alain Piché.   

Abstract

Ascites are commonly found in ovarian cancer patients with advanced disease and are rich in cellular components and growth-promoting factors. The purpose of this study was to assess the effect of malignant ascites on TRAIL-induced apoptosis. We demonstrate that malignant ascites obtained from women with advanced ovarian cancer protect tumor cells from TRAIL- and FasL-induced apoptosis but not against cisplatin-induced apoptosis. This antiapoptotic effect was consistently found among different malignant ascites while nonmalignant peritoneal fluids or conditioned medium from TRAIL-resistant cells failed to protect tumor cells against TRAIL killing. Malignant ascites strongly inhibits TRAIL-induced caspase-3 activation and PARP cleavage. Furthermore, ascites activate PI3K and its downstream target Akt and increases c-FLIP(S) protein levels without affecting ERK phosphorylation status. The antiapoptotic effect of malignant ascites is abrogated by the inhibition of PI3K with LY294002, by a specific inhibitor of Akt and by Akt siRNA. We further show that the pro-survival effect of ascites can be suppressed by down-regulation of c-FLIP(S). Our data indicate that malignant effusions protect against TRAIL-induced apoptosis by activating the PI3K/Akt pathway. These findings demonstrate that the tumor microenvironment may contribute to the resistance of ovarian cancer cells to death receptor-induced apoptosis. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17534891     DOI: 10.1002/ijc.22840

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  45 in total

1.  17-allylamino-17-demethoxygeldanamycin and MEK1/2 inhibitors kill GI tumor cells via Ca2+-dependent suppression of GRP78/BiP and induction of ceramide and reactive oxygen species.

Authors:  Teneille Walker; Clint Mitchell; Margaret A Park; Adly Yacoub; Mohamed Rahmani; Dieter Häussinger; Roland Reinehr; Christina Voelkel-Johnson; Paul B Fisher; Steven Grant; Paul Dent
Journal:  Mol Cancer Ther       Date:  2010-05-04       Impact factor: 6.261

2.  Mitogen-activated protein kinase kinase 1/2 inhibitors and 17-allylamino-17-demethoxygeldanamycin synergize to kill human gastrointestinal tumor cells in vitro via suppression of c-FLIP-s levels and activation of CD95.

Authors:  Margaret A Park; Guo Zhang; Clint Mitchell; Mohamed Rahmani; Hossein Hamed; Michael P Hagan; Adly Yacoub; David T Curiel; Paul B Fisher; Steven Grant; Paul Dent
Journal:  Mol Cancer Ther       Date:  2008-09       Impact factor: 6.261

3.  Role of malignant ascites on human mesothelial cells and their gene expression profiles.

Authors:  Isabelle Matte; Denis Lane; Dimcho Bachvarov; Claudine Rancourt; Alain Piché
Journal:  BMC Cancer       Date:  2014-04-24       Impact factor: 4.430

4.  Role of the body mass index in the genesis of ascites in ovarian cancer: a forensic case and review of the literature.

Authors:  Isabella Aquila; Pietrantonio Ricci; Alessandra Oliverio; Santo Gratteri
Journal:  BMJ Case Rep       Date:  2018-12-18

5.  Ascites IL-10 Promotes Ovarian Cancer Cell Migration.

Authors:  Denis Lane; Isabelle Matte; Perrine Garde-Granger; Paul Bessette; Alain Piché
Journal:  Cancer Microenviron       Date:  2018-07-23

6.  Asymmetric dimethylarginine induces endothelial nitric-oxide synthase mitochondrial redistribution through the nitration-mediated activation of Akt1.

Authors:  Ruslan Rafikov; Olga Rafikova; Saurabh Aggarwal; Christine Gross; Xutong Sun; Julin Desai; David Fulton; Stephen M Black
Journal:  J Biol Chem       Date:  2012-12-19       Impact factor: 5.157

Review 7.  Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research.

Authors:  Emma Kipps; David S P Tan; Stan B Kaye
Journal:  Nat Rev Cancer       Date:  2013-02-21       Impact factor: 60.716

Review 8.  Cellular FLICE-like inhibitory protein (C-FLIP): a novel target for cancer therapy.

Authors:  Ahmad R Safa; Travis W Day; Ching-Huang Wu
Journal:  Curr Cancer Drug Targets       Date:  2008-02       Impact factor: 3.428

9.  The prosurvival activity of ascites against TRAIL is associated with a shorter disease-free interval in patients with ovarian cancer.

Authors:  Denis Lane; Isabelle Matte; Claudine Rancourt; Alain Piché
Journal:  J Ovarian Res       Date:  2010-01-18       Impact factor: 4.234

10.  Activation of the Akt survival pathway contributes to TRAIL resistance in cancer cells.

Authors:  Jing Xu; Jun-Ying Zhou; Wei-Zen Wei; Gen Sheng Wu
Journal:  PLoS One       Date:  2010-04-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.